Is Alpine Immune Sciences, Inc. overvalued or undervalued?

As of 5 October 2023, Alpine Immune Sciences, Inc. has moved from a fair to an attractive rating. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%.
When compared to peers, such as Amgen with a price-to-earnings ratio of 18.5 and Regeneron Pharmaceuticals at 17.0, Alpine's metrics suggest it is trading at a discount. This valuation is further supported by the company's recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price.